NeuroDerm to Present at Upcoming Investor Conferences
Get Alerts NDRM Hot Sheet
Join SI Premium – FREE
REHOVOT, Israel, March 02, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will present at the following investor conferences:
- Cowen and Company 36th Annual Health Care Conference taking place in Boston, Massachusetts from March 7 – 9, 2016. Dr. Lieberman’s presentation will take place on Wednesday, March 9, at 11:20am ET.
- 28th Annual ROTH Conference taking place in Dana Point, California from March 13 – 16, 2016. Dr. Lieberman’s presentation will take place on Monday, March 14 at 9:30am PT, 12:30pm ET.
To access the live webcast of the presentations, please visit ir.neuroderm.com/. A replay will be available following the presentation.
About NeuroDermNeuroDerm is a clinical-stage pharmaceutical company developing central nervous system (CNS) product candidates that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration. NeuroDerm is headquartered in the Rabin Science Park, Rehovot, Israel.
NeuroDerm Contact:Oded S. Lieberman, PhD MBA, CEO[email protected]Tel.: +972-8-946 2729Cell: +1-617-517 6077
U.S. Investor Contact:David CareyLazar Partners Ltd.[email protected]+212-867-1762
Source: NeuroDerm Ltd.Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- A Moment of Xen Expands Its Wellness & Innovation Platform with Strategic Partnership Featuring Leela Quantum Tech's "Beyond the Signal" Series
- Best Crypto to Buy Now: Five Names and the Presale Now Asking $0.000015
- TruckerNavi Releases Free Trucker App on iOS and Android as Founder Publishes Two Compliance Books
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share